Systolic blood pressure reduction during the first 24 h in acute heart failure admission:Friend or foe? by 
  
 University of Groningen
Systolic blood pressure reduction during the first 24 h in acute heart failure admission
VERITAS Investigators; Cotter, Gad; Metra, Marco; Davison, Beth A.; Jondeau, Guillaume;
Cleland, John G. F.; Bourge, Robert C.; Milo, Olga; O'Connor, Christopher M.; Parker, John
D.
Published in:
European Journal of Heart Failure
DOI:
10.1002/ejhf.889
IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from
it. Please check the document version below.
Document Version
Publisher's PDF, also known as Version of record
Publication date:
2018
Link to publication in University of Groningen/UMCG research database
Citation for published version (APA):
VERITAS Investigators (2018). Systolic blood pressure reduction during the first 24 h in acute heart failure
admission: Friend or foe? European Journal of Heart Failure, 20(2), 317-322.
https://doi.org/10.1002/ejhf.889
Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the
author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).
Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the
number of authors shown on this cover page is limited to 10 maximum.
Download date: 12-11-2019
European Journal of Heart Failure (2018) 20, 317–322 RESEARCH ARTICLE
doi:10.1002/ejhf.889
Systolic blood pressure reduction during the
first 24 h in acute heart failure admission:
friend or foe?
Gad Cotter1*, Marco Metra2, Beth A. Davison1, Guillaume Jondeau3,
John G.F. Cleland4,5, Robert C. Bourge6, Olga Milo1, Christopher M. O’Connor7,
John D. Parker8, Guillermo Torre-Amione9, Dirk J. van Veldhuisen10, Isaac Kobrin11,
Maurizio Rainisio12, Stefanie Senger1, Christopher Edwards1, John J.V. McMurray13,
and John R. Teerlink14,15, for the VERITAS Investigators
1Momentum Research, Inc., Durham, NC, USA; 2Cardiology, Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, University of Brescia,
Brescia, Italy; 3Cardiology Service, Bichat Hospital, Paris, France; 4Department of Cardiology, University of Hull, Kingston upon Hull, UK; 5National Heart and Lung Institute,
Royal Brompton and Harefield Hospitals NHS Trust, Imperial College, London, UK; 6Department of Medicine, Division of Cardiovascular Disease, University of Alabama at
Birmingham, Birmingham, AL, USA; 7Duke Clinical Research Institute, Duke University Medical Center, Durham, NC, USA; 8Division of Cardiology, Mount Sinai Hospital,
Toronto, ON, Canada; 9Methodist DeBakey Heart and Vascular Center, Methodist Hospital, Houston, TX, USA; 10Department of Cardiovascular Disease, University Medical
Centre Groningen, Groningen, the Netherlands; 11Kobrin Associates GmbH, Basel, Switzerland; 12AbaNovus Srl, Sanremo, Italy; 13Department of Cardiovascular and Medical
Sciences, University of Glasgow, Glasgow, UK; 14Department of Medicine, Faculty of Cardiology, University of California San Francisco, San Francisco, CA, USA; and
15Department of Medicine, San Francisco Veterans Affairs Medical Center, San Francisco, CA, USA
Received 25 January 2017; revised 28 March 2017; accepted 12 April 2017 ; online publish-ahead-of-print 4 September 2017
Aims Changes in systolic blood pressure (SBP) during an admission for acute heart failure (AHF), especially those leading
to hypotension, have been suggested to increase the risk for adverse outcomes.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Methods
and results
We analysed associations of SBP decrease during the first 24 h from randomization with serum creatinine changes at
the last time-point available (72 h), using linear regression, and with 30- and 180-day outcomes, using Cox regression,
in 1257 patients in the VERITAS study. After multivariable adjustment for baseline SBP, greater SBP decrease at 24 h
from randomization was associated with greater creatinine increase at 72 h and greater risk for 30-day all-cause
death, worsening heart failure (HF) or HF readmission. The hazard ratio (HR) for each 1mmHg decrease in SBP
at 24 h for 30-day death, worsening HF or HF rehospitalization was 1.01 [95% confidence interval (CI) 1.00–1.02;
P= 0.021]. Similarly, the HR for each 1mmHg decrease in SBP at 24 h for 180-day all-cause mortality was 1.01
(95% CI 1.00–1.03; P= 0.038). The associations between SBP decrease and outcomes did not differ by tezosentan
treatment group, although tezosentan treatment was associated with a greater SBP decrease at 24 h.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Conclusions In the current post hoc analysis, SBP decrease during the first 24 h was associated with increased renal impairment
and adverse outcomes at 30 and 180 days. Caution, with special attention to blood pressure monitoring, should be
exercised when vasodilating agents are given to AHF patients.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
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Introduction
Vasodilating agents are among the recommended first-line thera-
pies in patients admitted for acute heart failure (AHF),1,2 despite a







. lack of evidence supporting their efficacy beyond the first hours of
admission.3 A drop in systolic blood pressure (SBP) during the first
days of admission has been observed in several studies;4–6 how-
ever, the predictors of SBP decreases and the associations of such
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blood pressure (BP) decreases with outcomes were not reported
in detail. An analysis of one small study did suggest that SBP reduc-
tion may be associated with untoward pathophysiological effects
such as worsening of kidney function.7 Such a potential deleterious
effect of an SBP decrease may explain, at least in part, the results
of some clinical studies in which pharmacologically induced SBP
decreases led to deteriorations in renal function and subsequent
adverse outcomes.8–10 This conclusion was strengthened by a
recent analysis of the Acute Study of Clinical Effectiveness of Nesir-
itide in Decompensated Heart Failure (ASCEND-HF) trial, which
suggested that hypotension is relatively common during AHF hos-
pitalization, and imposes a significant negative prognostic impact on
30-day outcomes.11 In the current analysis, we assessed predictors
of SBP changes at 24 h from study drug initiation (24–48 h from
admission) and their associations with worsening kidney function
and clinical outcomes in the Value of Endothelin Receptor Inhibi-
tion with Tezosentan in Acute Heart Failure Studies (VERITAS).4,5
Methods
The VERITAS project comprised two identical, concurrent randomized
trials that evaluated the efficacy of tezosentan administration within
24 h of hospital presentation for AHF.4,5 Inclusion criteria required
patients to have reported dyspnoea at rest after receipt of i.v. diuretics
and to have at least two of four objective signs of heart failure
(HF): elevated natriuretic peptides; pulmonary oedema on physical
examination; pulmonary congestion or oedema on chest X-ray, and
left ventricular systolic dysfunction evidenced by reduced ejection
fraction or wall motion index. Patients with SBP of ≤100mmHg, or
≤120mmHg if receiving a vasodilator, were excluded. Patients enrolled
in error more than 24 h after presentation and patients without a
measured SBP at 24 h were also excluded from the analyses.
Routine laboratory measurements at baseline, 24 h and 72 h were
obtained locally, whereas troponin I and brain natriuretic peptide levels
were assayed centrally. Patients were followed for worsening HF for
30 days, and vital status was assessed at 6months.
Statistical analysis
Summary statistics are reported as the mean and standard deviation
for continuous variables, and as the median (interquartile range) for
skewed variables; proportions in each category are presented for
categorical variables. Patients were grouped by tertiles of the change in
SBP from baseline to 24 h and baseline characteristics were compared
using analysis of variance (ANOVA) or Cochran–Mantel–Haenszel 𝜒2
tests, as appropriate.
Linear regression was used to model the associations of base-
line characteristics with the change in SBP from baseline to 24 h.
Non-linearity of the association between each continuous variable and
SBP change was assessed by testing the contribution of the non-linear
terms of a restricted cubic spline transformation with four knots. A
linear spline, quadratric or cubic polynomial, or log transformation,
was chosen, based on the Akaike’s information criterion, to model
non-linear associations. Ten multiple imputation datasets assuming mul-
tivariate normality were used for missing baseline covariates,12 and
parameter estimates were averaged over these imputation datasets
using Rubin’s algorithm.13 A multivariable model was selected in each
imputation dataset from among the baseline characteristics using back-



















































































.. included those covariates included in at least six of the 10 imputa-
tion datasets. The unadjusted association of SBP change at 24 h with
creatinine change at 72 h was assessed using linear regression. Logis-
tic regression was used to provide the odds ratios for the association
between SBP change at 24 h and an increase in creatinine of ≥0.3mg/dL
at 72 h, with covariates for multivariable adjustment selected using the
methodology described above.
Associations between the SBP changes and 30-day all-cause death or
HF readmission, and 180-day all-cause death, were examined using Cox
proportional hazards models. Potential confounding was addressed
through multivariable adjustment for baseline SBP and covariates
previously found to be prognostic of these outcomes.14
SAS version 9.3 (SAS Institute, Inc., Cary, NC, USA) was used for
all analyses.
Results
Of the 1449 patients randomized, 102 patients were enrolled at
more than 24 h from presentation and 90 patients lacked data on
the change in SBP at 24 h. These patients were excluded from the
dataset, leaving 1257 patients for analysis.
Patients’ baseline characteristics by tertiles of SBP change at 24 h
are presented in Table 1. Unadjusted and multivariable-adjusted
associations between baseline characteristics and SBP decrease
at 24 h are presented in Table 2. Predictors of a larger SBP drop
at 24 h were lack of atrial fibrillation or diabetes mellitus, higher
baseline SBP, longer QRS interval, higher blood urea nitrogen
(BUN), and lower white blood cell count. Respiratory rate, heart
rate and creatinine had non-linear relationships with SBP change.
Tezosentan treatment was associated with a larger mean SBP
decrease at 24 h [mean difference 6.17, 95% confidence interval
(CI) 4.39–7.96; P< 0.001].
Change in SBP at 24 h was inversely associated with change in
creatinine at 72 h (Figure 1). The relationship had an inflection point
around −15mmHg; that is, SBP decreases of >15mmHg were
associated with a numerical acceleration in creatinine increase,
although the departure from non-linearity was not statistically sig-
nificant (P= 0.5910). The percent is out of subjects in the analysis
population with non-missing creatinine change at day 3. 222/1068
(20.8%) had a creatinine change of ≥0.3mg/dL at 72 h. Patients with
larger decreases in SBP at 24 h were more likely to have a creati-
nine change of ≥0.3mg/dL at 72 h [odds ratio (OR) per 1mmHg
greater decrease in SBP: 1.01, 95% CI 1.00–1.02; P= 0.0272]. The
association of SBP change with creatinine increase did not differ sig-
nificantly by tezosentan treatment (interaction P= 0.7239). After
multivariable adjustment for factors found to be associated with a
creatinine change of ≥0.3mg/dL at 72 h in the VERITAS database
(supplementary material online, Table S1) [age, renal impairment,
time from admission to randomization, respiratory rate and esti-
mated glomerular filtration rate (eGFR)], the association of SBP
change with a creatinine change of ≥0.3mg/dL was of borderline
statistical significance (OR per 1mmHg decrease in SBP: 1.01,
95% CI 1.00–1.01; P= 0.0941). Tezosentan treatment was not
significantly associated with the risk for a creatinine increase of
≥0.3mg/dL, and further adjustment for tezosentan treatment did
not affect the association of SBP change with outcome.
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Table 1 Baseline characteristics by tertiles of systolic blood pressure (SBP) change to 24h
SBP change, mmHg All subjects








. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Age, years, mean± SD 71.0±12.01 69.9±11.93 69.9±12.49 0.3321 70.3± 12.14
Gender: male, n (%) 238 (56.3%) 263 (62.0%) 241 (58.8%) 0.4522 742 (59.0%)
Race: White, n (%) 353 (83.5%) 371 (87.5%) 362 (88.3%) 0.0409 1086 (86.4%)
Time to randomization, h,
mean± SD
10.2± 6.64 10.9± 7.02 11.4± 6.87 0.0423 10.8± 6.86
BMI, kg/m2, mean± SD 29.2± 6.47 28.8± 6.01 28.9± 6.28 0.7039 28.9± 6.25
Treated with tezosentan, n (%) 242 (57.2%) 242 (57.1%) 157 (38.3%) <0.0001 641 (51.0%)
Atrial fibrillation on admission, n
(%)
96 (22.7%) 112 (26.7%) 118 (29.1%) 0.0364 326 (26.2%)
History of CHF, n (%) 299 (70.9%) 325 (77.4%) 291 (71.9%) 0.7249 915 (73.4%)
History of COPD, n (%) 74 (17.5%) 84 (19.9%) 74 (18.0%) 0.8303 232 (18.5%)
History of diabetes, n (%) 211 (49.9%) 216 (51.1%) 184 (44.9%) 0.1519 611 (48.6%)
History of hyperlipidaemia, n (%) 142 (33.6%) 158 (37.4%) 145 (35.4%) 0.5818 445 (35.4%)
History of hypertension, n (%) 361 (85.3%) 329 (77.8%) 317 (77.3%) 0.0035 1007 (80.2%)
History of smoking, n (%) 28 (6.6%) 31 (7.3%) 37 (9.0%) 0.1926 96 (7.6%)
History of IHD, PVD, stroke, n
(%)
284 (67.1%) 302 (71.4%) 294 (71.7%) 0.1484 880 (70.1%)
History of mitral/aortic valve
disease, n (%)
75 (17.7%) 63 (14.9%) 65 (15.9%) 0.4573 203 (16.2%)
History of renal impairment, n
(%)
161 (38.2%) 166 (39.6%) 138 (34.1%) 0.2312 465 (37.3%)
History of liver disease, n (%) 30 (7.1%) 36 (8.6%) 31 (7.7%) 0.7631 97 (7.8%)
Previous PCI or CABG, n (%) 136 (32.2%) 159 (37.6%) 150 (36.6%) 0.1779 445 (35.4%)
On i.v. nitrates at randomization,
n (%)
73 (17.3%) 65 (15.3%) 69 (16.8%) 0.8622 207 (16.5%)
Furosemide i.v. over 24 h, mg,
median (IQR)
40.0 (0.0–120.0) 40.0 (0.0–120.0) 40.0 (0.0–120.0) 0.6385 40.0 (0.0–120.0)
ACE inhibitors, n (%) 224 (53.0%) 236 (55.7%) 204 (49.8%) 0.3622 664 (52.8%)
Beta-blockers, n (%) 201 (47.5%) 216 (50.9%) 176 (42.9%) 0.1905 593 (47.2%)
Angiotensin inhibitors, n (%) 55 (13.0%) 41 (9.7%) 35 (8.5%) 0.0345 131 (10.4%)
Calcium channel blockers, n (%) 78 (18.4%) 42 (9.9%) 63 (15.4%) 0.1980 183 (14.6%)
Oral loop diuretics, n (%) 136 (32.2%) 121 (28.5%) 115 (28.0%) 0.1931 372 (29.6%)
SBP, mmHg, mean± SD 147.3± 23.11 126.8±17.82 121.9±16.84 <0.0001 132.1± 22.37
Respiratory rate, breaths/min,
mean± SD
26.5± 4.43 26.0± 3.87 26.2± 4.22 0.1661 26.2± 4.18
Heart rate, b.p.m., mean± SD 84.4±16.97 83.6±18.16 83.2±17.78 0.5998 83.7± 17.63
ECG QRS interval, ms,
mean± SD
113.4± 35.40 114.2± 36.22 112.0± 34.82 0.6713 113.2± 35.48
Baseline dyspnoea VAS, mm,
mean± SD
62.8± 23.57 63.2± 23.12 61.9± 23.06 0.7096 62.6± 23.24
Albumin, g/L, mean± SD 38.0± 5.01 37.4± 5.27 37.8± 5.18 0.3683 37.7± 5.16
ALT, U/L, median (IQR) 18.2 (12.0–29.0) 18.6 (12.7–30.0) 18.7 (12.7–28.1) 0.4938 18.6 (12.6–29.1)
BUN, mmol/L, median (IQR) 8.2 (6.0–11.2) 8.3 (6.4–11.2) 7.9 (6.2–11.0) 0.0204 8.2 (6.2–11.1)
Creatinine, umol/L, mean± SD 115.7± 40.08 118.7± 36.82 116.1± 39.16 0.4711 116.8± 38.70
Haemoglobin, g/dL, mean± SD 13.4±1.88 13.3± 1.84 13.4± 1.94 0.9834 13.3±1.88
Sodium, mmol/L, mean± SD 139.1± 3.92 138.6± 4.06 138.6± 4.03 0.1231 138.7± 4.01
WBC count, ×109/L, mean± SD 9.7± 3.58 9.5± 3.70 10.2± 4.18 0.0162 9.8± 3.84
BNP, pg/mL, median (IQR) 437.0 (153.0–949.0) 419.0 (153.0–968.0) 404.0 (152.0–903.0) 0.6709 416.0 (153.0–936.0)
Troponin I, ng/mL, median (IQR) 0.0400 (0.0005–0.1260) 0.0350 (0.0005–0.1290) 0.0340 (0.0005–0.1285) 0.5221 0.0360 (0.0005–0.1275)
ALT, alanine aminotransferase; BMI, body mass index; BNP, brain natriuretic peptide; BUN, blood urea nitrogen; CABG, coronary artery bypass grafting; CHF, chronic
heart failure; COPD, chronic obstructive pulmonary disease; ECG, electrocardiogram; IHD, ischaemic heart disease; IQR, interquartile range; PCI, percutaneous coronary
intervention; PVD, peripheral vascular disease; SD, standard deviation; VAS, visual analogue scale; WBC, white blood cell (leucocyte).
aP-value according to Cochran–Mantel–Haenszel 𝜒2 test for categorical variables and F-test for continuous variables.
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Table 2 Univariable and multivariable associations of baseline characteristics with characteristics by tertiles of
systolic blood pressure (SBP) decrease at 24h
Predictor Univariable models Multivariable models
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Estimate for change of: Estimate (95% CI) P-value Estimate (95% CI) P-value
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Age 10 0.23 (−0.67 to 1.12) 0.623
Gender: male Yes vs. no −2.13 (−4.34 to 0.09) 0.060
Race: White Yes vs. no −3.13 (−6.31 to 0.04) 0.053
Time to randomization, h 1 −0.24 (−0.40 to −0.08) 0.003
BMI, kg/m2 1 0.06 (−0.12 to 0.24) 0.497
Atrial fibrillation on admission Yes vs. no −4.40 (−6.87 to −1.92) <0.001 −3.34 (−5.43 to −1.26) 0.002
History of CHF Yes vs. no −0.74 (−3.21 to 1.74) 0.561
History of COPD Yes vs. no −0.67 (−3.48 to 2.14) 0.642
History of diabetes Yes vs. no 0.80 (−1.38 to 2.99) 0.470 −2.22 (−4.04 to −0.40) 0.017
History of hyperlipidaemia Yes vs. no −0.49 (−2.77 to 1.79) 0.675
History of hypertension Yes vs. no 4.00 (1.28–6.72) 0.004
History of smoking Yes vs. no −1.60 (−5.70 to 2.51) 0.446
History of IHD, PVD, stroke Yes vs. no −0.73 (−3.11 to 1.65) 0.550
History of mitral/aortic valve disease Yes vs. no 0.75 (−2.21 to 3.71) 0.618
History of renal impairment Yes vs. no 0.39 (−1.87 to 2.66) 0.732
History of liver disease Yes vs. no 0.23 (−3.85 to 4.31) 0.912
Previous PCI or CABG Yes vs. no −1.98 (−4.26 to 0.30) 0.089
On i.v. nitrates at randomization Yes vs. no −0.12 (−3.06 to 2.82) 0.936
Furosemide i.v. over 24 h, mg 5 −0.01 (−0.05 to 0.04) 0.810
Systolic blood pressure, mmHg 1 0.47 (0.43–0.51) <0.001 0.49 (0.45–0.53) <0.001
Respiratory rate ≤24 breaths/min 5 −0.40 (−4.35 to 3.56) 0.036
Respiratory rate >24 breaths/min 5 2.03 (0.46–3.59)
Heart rate, b.p.m.a 94.50 vs. 82.00 0.35 (−0.42 to 1.13) 0.357 1.33 (0.67–1.99) <0.001
82.00 vs. 71.00 0.90 (−0.05 to 1.85) 1.77 (0.98–2.57)
ECG QRS interval, ms 1 0.00 (−0.03 to 0.04) 0.777 0.05 (0.03–0.08) <0.001
Dyspnoea VAS 1 0.02 (−0.03 to 0.06) 0.478
Albumin, g/L 1 0.09 (−0.15 to 0.32) 0.469
ALT, U/I Doubling −0.80 (−1.93 to 0.34) 0.169
BUN, mmol/L Doubling 0.38 (−1.21 to 1.96) 0.642 1.53 (0.18–2.87) 0.026
Creatinine ≤120 μmol/L 5 −0.32 (−0.65 to 0.01) 0.099
Creatinine >120 μmol/L 5 0.22 (−0.02 to 0.46)
Haemoglobin, g/dL 1 −0.00 (−0.58 to 0.58) 0.992
Sodium, mmol/L 3 0.67 (−0.15 to 1.49) 0.112
WBC count, ×109/L 1 −0.27 (−0.56 to 0.01) 0.060 −0.33 (−0.56 to −0.09) 0.006
BNP, pg/mL Doubling 0.29 (−0.28 to 0.86) 0.314
Troponin I, ng/mL Doubling −0.03 (−0.30 to 0.24) 0.848
Treated with tezosetan Yes vs. no 6.85 (4.71 to 9.00) <0.001 6.17 (4.39–7.96) <0.001
BMI, body mass index; BNP, brain natriuretic peptide; BUN, blood urea nitrogen; CABG, coronary artery bypass grafting; CHF, chronic heart failure; CI, confidence interval;
COPD, chronic obstructive pulmonary disease; ECG, electrocardiogram; IHD, ischaemic heart disease; PCI, percutaneous coronary intervention; PVD, peripheral vascular
disease; WBC, white blood cell (leucocyte).
aNon-linear association modelled as quadratic transformation. Estimates for the 75th percentile vs. the median, and for the median vs. the 25th percentile are presented.
Similarly, SBP decrease at 24 h was associated with a greater
risk for adverse outcomes at both 30 days and 180 days. All-cause
death, worsening HF or HF readmission within 30 days occurred
in 395 of 1257 (31.4%) patients and 165 of 1257 (13.1%) patients
died within 180 days. After multivariable adjustment, the hazard
ratio (HR) for each 1mmHg decrease in SBP at 24 h for 30-day
death, worsening HF or HF rehospitalization was 1.01 (95%
CI 1.00–1.02; P= 0.021), and this association did not differ by
randomized treatment (interaction P= 0.3409). A larger decrease
at 24 h in SBP was also associated with an increased risk for
all-cause mortality at 180 days. For 30-day death, worsening HF

















. age, heart rate, respiratory rate, history of chronic HF, history
of diabetes, history of chronic obstructive pulmonary disease
(COPD), SBP, renal impairment, baseline score for dyspnoea on
a visual analogue scale (VAS), albumin, BUN, haemoglobin and
sodium.14 For 180-day all-cause death, covariates for multivariable
adjustment were age, heart rate, history of ischaemic heart dis-
ease, peripheral vascular disease or stroke, SBP, baseline dyspnoea
VAS, history of COPD, albumin, BUN, white blood cell count
and sodium.14 After multivariable adjustment, the HR for each
1mmHg decrease in SBP at 24 h for 180-day all-cause mortality
was 1.01 (95% CI 1.00–1.03; P= 0.038). There was no interaction
between SBP decrease and outcomes in tezosentan-treated vs.
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Figure 1 Association of systolic blood pressure (SBP) change
at 24 h with creatinine change at 72 h. The predicted value of
the change in creatinine relative to the average change is plotted
as a restricted cubic spline function of SBP change with knots
at −45, −18, −4 and 20mmHg. Vertical tick marks represent
individual patient values of SBP change. Vertical reference lines for
the 5th, 25th, 50th, 75th and 95th percentiles of the SBP change
distribution are shown.
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Figure 2 Association of systolic blood pressure (SBP) decrease
by time from randomization with 180-day all-cause death, show-
ing the hazard ratio per 1mmHg greater decrease in SBP with
associated 95% confidence intervals (CIs).
placebo-treated patients (interaction P= 0.1414). Figure 2 depicts
the association between 180-day mortality and SBP decrease at
different time-points to 24 h and suggests a lack of significance in
the first 12 h and an increased effect of SBP decrease with time.
Discussion
The present analysis of VERITAS data suggests an inverse corre-
lation between SBP changes and renal function as measured by
creatinine changes at 72 h, as well as 30- and 180-day outcomes
in patients with AHF. Patients with larger decreases in BP were



















































































.. for 30-day death, worsening HF or HF readmission, and 180-day
mortality.
The results of these analyses are largely in line with those of
previous studies, and both confirm and supplement them. In a
small analysis of the Pre-RELAX-AHF (Relaxin in Acute Heart
Failure) Phase 2 study, Voors et al.7 showed that BP decrease
is associated with renal function deterioration. An analysis of
the larger ASCEND-HF study11 demonstrated that hypotension,
strictly defined as an SBP decrease to <90mmHg regardless of
initial BP, was associated with increased risk for adverse outcome
at 30 days, but not with renal impairment at day10 or discharge. As
the restrictions imposed by the selection of the subgroup analysed
in ASCEND-HF (i.e. patients with hypotension defined by a specific
cut-off and assessment of renal function distant from the event)
limit the analysis to a specific subgroup of patients, it is possible that
a relative decrease in SBP rather than the reaching of an arbitrary
threshold is more important prognostically. Indeed, in the present
analysis, baseline-adjusted SBP decreases were associated both
with more adverse outcomes and with more renal impairment,
regardless of the magnitude of decrease in SBP.
The relationship between SBP changes and outcomes after treat-
ment with vasodilating agents has not been thoroughly studied
in the past. In the current analysis, no interaction was found
between SBP decrease, drug therapy and outcomes (P= 0.1414
for 180-day mortality), although, as noted previously, active ther-
apy with tezosentan was associated with a greater decrease
in SBP. Thus, the increased risk associated with a larger drop
in SBP may have neutralized the beneficial effects of the new
treatment.
Previous studies have suggested that such SBP lowering induced
by active interventions may lead to more adverse outcomes. In
earlier studies, in which doses of nesiritide higher than those given
in ASCEND-HF were administered, nesiritide therapy led to more
hypotension, renal impairment and increased mortality.9 However,
this finding was not replicated in the ASCEND-HF study, in which
lower doses of nesiritide were administered. In the REVIVE study,
similar findings were reported and greater hypotension in the
active arm was associated with a trend towards earlier mortality,8
especially in patients enrolled with lower BP at screening. Finally, in
the recently reported TRUE-AHF study, administration of ularitide
was associated with a greater SBP decrease in the active arm
(approximately 10mmHg at 24 h), an increase in creatinine and
a numerical increase in early mortality at 180–240 days.10 These
results can be explained by some negative effects of BP decreases
on perfusion in end organs such as kidneys,7 although data on the
mechanism behind why such decreases in BP may be detrimental
are not available. These findings may underestimate the true
negative effects of BP reduction in AHF as creatinine is not a perfect
measure of kidney dysfunction.15 Further, no studies examining the
effects of agents with vasodilating effects have ever demonstrated
beneficial effects in patients with AHF beyond the first few hours
of admission. Most importantly, the effects of administration of
i.v. nitrates beyond the first 1–2 h of admission have never been
examined in detail, although these agents are recommended in
guidelines for the treatment of AHF.1 Interestingly, the present
data also show that early changes in SBP have no relationship
© 2017 The Authors
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with outcomes, whereas changes that occur beyond 12 h from
admission are associated with worse outcomes. Hence, the totality
of the evidence – in both the current and previous analyses, as well
as prospective studies – begs the question of whether vasodilation,
long held as a pillar of therapy for AHF, does indeed benefit
patients beyond the first hours of administration, especially once
normal SBP values are reached. These data would suggest that our
knowledge of the effects of vasodilation in AHF is incomplete and
studies to examine such effects may be urgently needed. In the
meantime, physicians should exercise caution when administering
vasodilating agents to patients with AHF, especially when they cause
a significant reduction in SBP of >15–25mmHg or when a low SBP
is reached.
Limitations
The current analysis is a post hoc analysis of data from the VERITAS
project and as such should be seen as hypothesis-generating and
not as definitive.
Conclusions
Systolic blood pressure decreases in patients with AHF are associ-
ated with more early renal impairment and an increase in adverse
outcomes at 30 and 180 days. Studies examining the effects of
vasodilating agents such as i.v. nitrates in AHF are urgently needed
and, until such studies are performed, caution should be exercised
in the administration of these agents to patients with AHF, espe-
cially when significant falls in SBP are observed.
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